Skip to content
10-K

Annual Report

Elevation Oncology, Inc.

0001558370-25-002397

← back to feed
Filed
Mar 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 28, 2025 59.22M sh
Shares Diluted FY 2024 · Dec 31, 2024 57.28M sh
Shares Diluted restated FY 2024 · Dec 31, 2023 36.52M sh
Stock Repurchased FY 2024 · Dec 31, 2024 $48K
Stock Repurchased FY 2024 · Dec 31, 2023 $24K
Operating Cash Flow FY 2024 · Dec 31, 2024 −$36.36M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$56.18M
Long Term Debt FY 2024 · Dec 31, 2024 $31.13M
Long Term Debt FY 2024 · Dec 31, 2023 $30.14M
Cash And Equivalents FY 2024 · Dec 31, 2024 $49.46M
Cash And Equivalents FY 2024 · Dec 31, 2023 $49.26M
Stockholders Equity FY 2024 · Dec 31, 2024 $60.03M
Stockholders Equity FY 2024 · Dec 31, 2023 $54.81M
Stockholders Equity FY 2024 · Dec 31, 2022 $49.03M
Current Liabilities FY 2024 · Dec 31, 2024 $4.47M
Current Liabilities FY 2024 · Dec 31, 2023 $4.15M
Total Liabilities FY 2024 · Dec 31, 2024 $35.6M
Total Liabilities FY 2024 · Dec 31, 2023 $34.28M
Current Assets FY 2024 · Dec 31, 2024 $94.73M
Current Assets FY 2024 · Dec 31, 2023 $87.96M
Total Assets FY 2024 · Dec 31, 2024 $95.63M
Total Assets FY 2024 · Dec 31, 2023 $89.09M
Eps Diluted FY 2024 · Dec 31, 2024 −$0.78
Eps Diluted restated FY 2024 · Dec 31, 2023 −$1.25
Eps Basic FY 2024 · Dec 31, 2024 −$0.78
Eps Basic restated FY 2024 · Dec 31, 2023 −$1.25
Sga Expense FY 2024 · Dec 31, 2024 $16.11M
Sga Expense FY 2024 · Dec 31, 2023 $14.9M
Rd Expense FY 2024 · Dec 31, 2024 $28.6M
Rd Expense FY 2024 · Dec 31, 2023 $25.43M
Net Income FY 2024 · Dec 31, 2024 −$44.49M
Net Income FY 2024 · Dec 31, 2023 −$45.7M
Operating Income FY 2024 · Dec 31, 2024 −$44.7M
Operating Income FY 2024 · Dec 31, 2023 −$45.45M